A systematic methodology review of phase I radiation dose escalation trials. 2010

Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. madelon.pijls@maastro.nl

OBJECTIVE The purpose of this review is to evaluate the methodology used in published phase I radiotherapy (RT) dose escalation trials. A specific emphasis was placed on the frequency of reporting late complications as endpoint. METHODS We performed a systematic literature review using a predefined search strategy to identify all phase I trials reporting on external radiotherapy dose escalation in cancer patients. RESULTS Fifty-three trials (phase I: n = 36, phase I-II: n = 17) fulfilled the inclusion criteria. Of these, 20 used a modified Fibonacci design for the RT dose escalation, but 32 did not specify a design. Late toxicity was variously defined as > 3 months (n = 43) or > 6 months (n = 3) after RT, or not defined (n = 7). In only nine studies the maximum tolerated dose (MTD) was related to late toxicity, while only half the studies reported the minimum follow-up period for dose escalation (n = 26). CONCLUSIONS In phase I RT trials, late complications are often not taken into account and there is currently no consensus on the methodology used for radiation dose escalation studies. We therefore propose a decision-tree algorithm which depends on the endpoint selected and whether a validated early surrogate endpoint is available, in order to choose the most appropriate study design.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011829 Radiation Dosage The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv). Sievert Units,Dosage, Radiation,Gray Units,Gy Radiation,Sv Radiation Dose Equivalent,Dosages, Radiation,Radiation Dosages,Units, Gray,Units, Sievert
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm
D012196 Review Literature as Topic Works about published materials which provide an examination of recent or current literature. These articles can cover a wide range of subject matter at various levels of completeness and comprehensiveness based on analyses of literature that may include research findings. The review may reflect the state of the art and may also include reviews as a literary form. State-of-the-Art Review,State-of-the-Art Reviews,Review, State-of-the-Art,Reviews, State-of-the-Art,State of the Art Review,State of the Art Reviews
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017321 Clinical Trials, Phase I as Topic Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries. Clinical Trials, Phase I,Drug Evaluation, FDA Phase I,Evaluation Studies, FDA Phase I,Human Microdosing Trial,Phase 1 Clinical Trial,Phase I Clinical Trial,Phase I Clinical Trials,Clinical Trials, Phase 1,Drug Evaluation, FDA Phase 1,Drug Evaluation, FDA Phase I as Topic,Evaluation Studies, FDA Phase 1,Human Microdosing Trials,Microdosing Trials, Human,Phase 1 Clinical Trials,Microdosing Trial, Human,Trial, Human Microdosing,Trials, Human Microdosing

Related Publications

Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
May 2009, Journal of the National Cancer Institute,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
November 2010, European journal of cancer (Oxford, England : 1990),
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
December 2009, Journal of the National Cancer Institute,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
April 2021, BMC medical research methodology,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
June 2018, Statistical papers (Berlin, Germany),
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
January 2021, BMC cancer,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
May 1998, Statistics in medicine,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
September 2014, Clinical cancer research : an official journal of the American Association for Cancer Research,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
October 2007, Computer methods and programs in biomedicine,
Madelon Pijls-Johannesma, and Ghislaine van Mastrigt, and Steve M Hahn, and Dirk De Ruysscher, and Brigitta G Baumert, and Guido Lammering, and Jeroen Buijsen, and Soren M Bentzen, and Yolande Lievens, and Andrew Kramar, and Philippe Lambin
July 2015, Contemporary clinical trials,
Copied contents to your clipboard!